<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11749">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105506</url>
  </required_header>
  <id_info>
    <org_study_id>NL38212</org_study_id>
    <nct_id>NCT02105506</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses</brief_title>
  <acronym>SAFE-T</acronym>
  <official_title>Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R. van Hillegersberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <authority>The Netherlands: IRB (METC University Medical Centre Utrecht)</authority>
    <authority>The Netherlands: CCMO</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The construction of esophageal anastomoses is associated with considerable risk
      at postoperative anastomotic leakage. Application of TachoSil®, a tissue sealant with human
      fibrinogen and thrombin, can improve strength of the esophageal anastomosis and potentially
      prevent anastomotic leakage.

      Objective: Evaluation of feasibility and safety of TachoSil® application on esophageal
      anastomoses.

      Study design: Non-randomized, non-blinded, single-center intervention study. Study
      population: Patients, 18-80 years old, undergoing an elective total gastrectomy with an
      esophago-jejunostomy or esophagectomy with a planned esophagogastric anastomosis will be
      enrolled. A total number of 15 patients will be included in the study.

      Intervention: Gastric or esophageal resection will be executed according to the common
      procedures used in the UMC Utrecht. After construction of the esophageal anastomosis, all
      enrolled participants will receive a TachoSil® patch, which will be applied on the
      esophageal anastomosis intra-operatively. Hence, TachoSil® is used as an add-on therapy.
      TachoSil® will be degraded enzymatically in a period of approximately 24 weeks after
      application.

      Main study parameters/endpoints: The primary endpoint is feasibility, which is assessed by
      evaluation of adherence of the patch. A time-action analysis of the application of the
      Tachosil patch will be performed.

      Nature and extent of the burden associated with participation: The burden for the patient is
      minimal. The total surgical procedure will be prolonged with 10-15 minutes. Postoperative
      care and outpatient visits do not differ from regular protocol. TachoSil® is approved and
      registered for supportive treatment in surgery for improvement of haemostasis and to promote
      tissue sealing by the European Commission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>Surgical procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>The adherence of the Tachosil patch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>within the first 30 days (plus or minus 3 days) after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Esophageal Disease</condition>
  <condition>Gastric Disease</condition>
  <arm_group>
    <arm_group_label>Tachosil patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tachosil patch</intervention_name>
    <description>n/a</description>
    <arm_group_label>Tachosil patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing an elective total gastrectomy with an esophago-jejunostomy or
             esophagectomy with a planned esophagogastric anastomosis

          -  Male and female gender

          -  Ages 18-80

          -  Signed informed consent

          -  For females of childbearing potential:

               -  Patient uses a reliable contraceptive method: contraceptive pill, intrauterine
                  device, subdermal implantation, or transdermal patch

               -  Patient has a negative serum or urine pregnancy test.

        Exclusion Criteria:

          -  Emergency resections of esophagus of stomach

          -  Unsigned informed consent

          -  History of hypersensitivity reactions to human fibrinogen, human thrombin, or
             collagen.

          -  Patients having difficulty understanding Dutch and English

          -  Mentally incapable patients

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leonie Haverkamp, MD</last_name>
    <phone>+31887555555</phone>
    <phone_ext>1731</phone_ext>
    <email>L.Haverkamp@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard van Hillegersberg, MD PhD</last_name>
    <phone>+31887558074</phone>
    <email>R.vanHillegersberg@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonie Haverkamp, MD</last_name>
      <phone>+31887555555</phone>
      <phone_ext>1731</phone_ext>
      <email>L.Haverkamp@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Richard van Hillegersberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jelle P Ruurda, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonie Haverkamp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>R. van Hillegersberg</investigator_full_name>
    <investigator_title>Prof. R. van Hillegersberg, surgeon</investigator_title>
  </responsible_party>
  <keyword>Esophagus</keyword>
  <keyword>Stomach</keyword>
  <keyword>Resection</keyword>
  <keyword>Esophageal disease requiring surgery</keyword>
  <keyword>Gastric disease requiring surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Diseases</mesh_term>
    <mesh_term>Stomach Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
